Tango Therapeutics TNGX TNG908Direct Program Expenses-RD — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's tng908direct program expenses-rd — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's tng908direct program expenses-rd — research and development expense?
- Tango Therapeutics (TNGX) reported tng908direct program expenses-rd — research and development expense of $581K in Q1 2026.
- How has Tango Therapeutics's tng908direct program expenses-rd — research and development expense changed year-over-year?
- Tango Therapeutics's tng908direct program expenses-rd — research and development expense decreased by 66.1% year-over-year, from $1.71M to $581K.
- What is the long-term trend for Tango Therapeutics's tng908direct program expenses-rd — research and development expense?
- Over 3 years (2022 to 2025), Tango Therapeutics's tng908direct program expenses-rd — research and development expense has grown at a -26.8% compound annual growth rate (CAGR), from $12.82M to $5.03M.
- What does tng908direct program expenses-rd — research and development expense mean?
- This metric represents the direct research and development expenditures specifically allocated to the TNG908 clinical program. It captures the costs associated with preclinical studies, clinical trial execution, and manufacturing development for this specific precision oncology asset. Tracking these expenses allows investors to evaluate the capital intensity and progress of the company's lead therapeutic candidates.